- June 2015: Bio-Reference Laboratories Inc. (NASDAQ: BRLI), the nation’s third largest full-service clinical laboratory, was acquired by OPKO Health (NYSE: OPK) of Miami, Florida, for. $1.47 billion
- No cash is involved in this purchase. OPKO will pay for the acquisition by exchanging 2.75 shares of OPKO common stock for each share of BRLI common stock. The deal puts a value of BRLI’s common stock of $52.58 per share, the companies announced.
*****
- 6/13/13 12:19PM Bio-Reference Labs (BRLI) to launch comprehensive breast cancer genetic test. GeneDx, a subsidiary of Bio-Reference Laboratories (BRLI), announced its intention to launch a suite of comprehensive genetic tests for inherited cancers including BRCA1 and BRCA2 genes, given the Supreme Court's ruling in the Association for Molecular Pathology vs. Myriad Genetics (MYGN) case. GeneDx will offer a 27-gene panel for breast and ovarian cancers. GeneDx will also provide next generation sequencing based multi-gene panels for gastrointestinal and colorectal cancers, pancreatic cancer, endometrial cancer and renal cell carcinoma. The Company has indicated that it intends to introduce all of these panels as early as August 1, 2013.
Address
481 Edward H Ross Dr
ELMWOOD PARK, NJ 07407-3118
United States
ELMWOOD PARK, NJ 07407-3118
United States
Website
http://www.bioreference.comKey stats and ratios
| Q2 (Apr '15) | 2014 | |
| Net profit margin | 4.67% | 5.62% |
| Operating margin | 8.45% | 10.02% |
| EBITD margin | - | 13.05% |
| Return on average assets | 8.38% | 10.39% |
| Return on average equity | 12.67% | 15.84% |
| Employees | 3,406 |
No comments:
Post a Comment